These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
91 related articles for article (PubMed ID: 2717043)
1. [Cardiomyopathy due to adriamycin: the possibility of its prevention. Monitoring by noninvasive technics]. Bianchi L; Bertocchi C; Felci U; Ferrario G; Giani P; Mariani L; Medolago G; Sarti E Minerva Med; 1989 Mar; 80(3):215-26. PubMed ID: 2717043 [TBL] [Abstract][Full Text] [Related]
2. Cardiac sequelae of doxorubicin and paclitaxel as induction chemotherapy prior to high-dose chemotherapy and peripheral blood progenitor cell transplantation in women with high-risk primary or metastatic breast cancer. Klein JL; Rey PM; Dansey RD; Karanes C; Du W; Abella E; Cassells L; Hamm C; Peters WP; Baynes RD Bone Marrow Transplant; 2000 May; 25(10):1047-52. PubMed ID: 10828864 [TBL] [Abstract][Full Text] [Related]
3. [Pharmacokinetics and acute signs of cardiac toxicity during doxorubicin therapy]. Lenzhofer R; Schneeweiss B; Rameis H; Eichler H; Graninger W; Dittrich C; Dudczak R; Ganzinger U; Gasic S; Moser K Wien Klin Wochenschr; 1983 Jan; 95(2):52-5. PubMed ID: 6858169 [TBL] [Abstract][Full Text] [Related]
4. [An evaluation of the cardioprotective action of the preparation ICRF-187 (Cardioxane) during the treatment of breast cancer with large doses of adriamycin]. Min'kov ED; Niu-Tian-de GB; Shkhvatsabaia LV; Bagdasarov IuB; Zaĭtseva TI; Odzharova AA Ter Arkh; 1994; 66(10):64-6. PubMed ID: 7863453 [TBL] [Abstract][Full Text] [Related]
5. [Monitoring of cardiac function during doxorubicin therapy in metastasized breast cancer. Measuring systolic time interval]. Lenzhofer R; Dudczak R; Dittrich C; Gumhold G; Moser K; Spitzy KH Dtsch Med Wochenschr; 1983 May; 108(20):771-5. PubMed ID: 6840008 [TBL] [Abstract][Full Text] [Related]
6. [Prevention of cardiotoxicity of doxorubicin (Adriamycin) using cardioxane (ICRF-187, dexrazoxane) in the combination chemotherapy of disseminated breast cancer]. Gershanovich ML; Moiceenko VM; Orlova RV Vopr Onkol; 1993; 39(1-3):26-32. PubMed ID: 8073671 [TBL] [Abstract][Full Text] [Related]
8. [Echocardiography with angiotensin administration in the diagnosis of adriamycin-induced cardiomyopathy]. Göldel N; Autenrieth G; Werdan K; Knesewitsch P; Wilmanns W Z Kardiol; 1989 May; 78(5):320-7. PubMed ID: 2735093 [TBL] [Abstract][Full Text] [Related]
9. [Doxorubicin-induced cardiomyopathy: hemodynamic studies for evaluating the limit of therapeutic risk]. Lenzhofer R; Magometschnigg D Z Kardiol; 1983 May; 72(5):297-303. PubMed ID: 6880337 [TBL] [Abstract][Full Text] [Related]
10. [Congestive cardiomyopathy after doxorubicin (adriamycin)author's transl)]. Kaduk B; Seiler G Dtsch Med Wochenschr; 1977 Dec; 102(49):1813-7. PubMed ID: 271071 [TBL] [Abstract][Full Text] [Related]
11. Adriamycin-induced myocardial toxicity: new solutions for an old problem? Outomuro D; Grana DR; Azzato F; Milei J Int J Cardiol; 2007 Apr; 117(1):6-15. PubMed ID: 16863672 [TBL] [Abstract][Full Text] [Related]
12. Liposomal doxorubicin (Caelyx) in advanced pretreated soft tissue sarcomas: a phase II study of the Italian Sarcoma Group (ISG). Toma S; Tucci A; Villani G; Carteni G; Spadini N; Palumbo R Anticancer Res; 2000; 20(1B):485-91. PubMed ID: 10769710 [TBL] [Abstract][Full Text] [Related]
13. [Diagnosis of adriamycin myocardiopathy using echocardiography]. Harpf H; Lehnert M; Tschech G Acta Med Austriaca Suppl; 1979; 6():341-3. PubMed ID: 299226 [TBL] [Abstract][Full Text] [Related]
14. 1-year followup of cardiac status after adriamycin therapy. Friedman MJ; Ewy GA; Jones SE; Cruze D; Moon TE Cancer Treat Rep; 1979; 63(11-12):1809-16. PubMed ID: 526915 [TBL] [Abstract][Full Text] [Related]
15. Use of dexrazoxane and other strategies to prevent cardiomyopathy associated with doxorubicin-taxane combinations. Sparano JA Semin Oncol; 1998 Aug; 25(4 Suppl 10):66-71. PubMed ID: 9768827 [TBL] [Abstract][Full Text] [Related]
16. Phase I/II study of dose-intense doxorubicin/paclitaxel/cyclophosphamide with peripheral blood progenitor cells and cytokine support in patients with metastatic breast cancer. Rahman Z; Champlin R; Rondon G; Frye D; Valero V; Mehra R; Hortobagyi G Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-77-S17-80. PubMed ID: 9374100 [TBL] [Abstract][Full Text] [Related]
17. Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults. Hequet O; Le QH; Moullet I; Pauli E; Salles G; Espinouse D; Dumontet C; Thieblemont C; Arnaud P; Antal D; Bouafia F; Coiffier B J Clin Oncol; 2004 May; 22(10):1864-71. PubMed ID: 15143078 [TBL] [Abstract][Full Text] [Related]
18. [Risk of cardiotoxicity of combination treatment radiotherapy and chemotherapy of locally advanced breast carcinoma stage III]. Bustová I Klin Onkol; 2009; 22(1):17-21. PubMed ID: 19534435 [TBL] [Abstract][Full Text] [Related]
19. Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer. Dhingra K; Frye D; Newman RA; Walters R; Theriault R; Fraschini G; Smith T; Buzdar A; Hortobagyi GN Clin Cancer Res; 1995 Jul; 1(7):691-7. PubMed ID: 9816034 [TBL] [Abstract][Full Text] [Related]
20. Noninvasive methods for the early detection of doxorubicin-induced cardiomyopathy. Lenzhofer R; Dudczak R; Gumhold G; Graninger W; Moser K; Spitzy KH J Cancer Res Clin Oncol; 1983; 106(2):136-42. PubMed ID: 6630284 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]